In our study, we identified two different alternatively-activated TGF-β signaling pathways, and the E2F5-related sub-pathway is related to breast cancer, while the E2F4 related one is a risk for metastasis and potential worse survival. The gene discussed is E2F4; the disease is breast carcinoma.